We performed ROC analysis for each marker and found that four markers (ACSL4, ITGB3, ITGA5 and FOLR1) had an area under the curve (AUC) that is higher for early stage compared to healthy plasma versus late stage compared to healthy plasma (Supplementary Table 2). Since this sample set of diseased patients is relatively small, we proceeded with calculating all the ovarian cancer patients (n = 10) together instead of in separate groups (early or late stage) against the healthy controls (n = 20). The gene discussed is ITGB3; the disease is ovarian cancer.